title: Central nervous stimulants facilitate sexual behavior in male rats with medial prefrontal cortex lesions.
abstract: Male rats with lesions of the cerebral cortex near the midline in the frontal region destroying most of the cingulate cortex and producing some damage to adjacent frontal areas have very long mount and intromission latencies. Otherwise their sexual behavior is essentially normal. The dopamine releasers amfonelic acid, 0.5 mg/kg, and amphetamine, 1 mg/kg, reduced the mount and intromission latencies in males with such lesions. Caffeine, 30 mg/kg, had similar effects. None of the drugs modified sexual behavior in intact males. It has been suggested that medial prefrontal lesions reduce the animal's reactivity to environmental stimuli, and hence renders the activation of sexual behavior difficult. Present results show that stimulant drugs are capable of compensating for this reduced reactivity. The possible mechanisms behind this effect are discussed. The lesion had also a small but consistent effect on the intromission ratio, suggesting some motor impairment. The effect on intromission ratio was not reduced by the drugs, suggesting that the lesion's motor consequences are mediated by mechanisms different from those controlling behavioral reactivity. The noradrenaline precursor dl-threo-dihydroxyphenylserine, 10 mg/kg, in combination with carbidopa, 50 mg/kg, increased mount and intromission latencies in both intact and lesioned males. Thus, activation of noradrenergic neurotransmission had effects opposite to those found after activation of dopaminergic transmission. Noradrenergic stimulation cannot, therefore, be important for the effects of amphetamine or amfonelic acid.
authors.affiliation: Department of Psychology, Universidad Anáhuac, Mexico City, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Agmo
authors.forename: A
authors.initials: A
authors.lastname: Villalpando
mesh_terms: D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D015103:Droxidopa / Q000494:pharmacology; D004542:Ejaculation / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D008297:Male; D009268:Nalidixic Acid / Q000031:analogs & derivatives; D009287:Naphthyridines / Q000494:pharmacology; D009638:Norepinephrine / Q000502:physiology; D010052:Ovariectomy; D017397:Prefrontal Cortex / Q000502:physiology*; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012726:Sexual Behavior, Animal / Q000187:drug effects* / Q000502:physiology
chemical_list: D000697:Central Nervous System Stimulants; D009287:Naphthyridines; D009268:Nalidixic Acid; D002110:Caffeine; D011374:Progesterone; D004958:Estradiol; D000661:Amphetamine; D015103:Droxidopa; C006486:amfonelic acid; D004298:Dopamine; D009638:Norepinephrine